{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:08:20Z","timestamp":1775027300941,"version":"3.50.1"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":79,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017336","name":"Dipartimenti di Eccellenza","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008991","name":"Universit\u00e0 degli Studi Roma Tre","doi-asserted-by":"publisher","award":["314-337"],"award-info":[{"award-number":["314-337"]}],"id":[{"id":"10.13039\/100008991","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.bcp.2023.115675","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T17:37:23Z","timestamp":1688405843000},"page":"115675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RAR\u03b1 and overcomes ATRA resistance in acute promyelocytic leukemia cells"],"prefix":"10.1016","volume":"214","author":[{"given":"Maria","family":"Franza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Albanesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Leone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Acconcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"di Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2023.115675_b0005","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"11","key":"10.1016\/j.bcp.2023.115675_b0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/iub.1918","article-title":"Are DNA damage response kinases a target for the differentiation treatment of acute myeloid leukemia?","volume":"70","author":"Pennisi","year":"2018","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bcp.2023.115675_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.12.003","article-title":"Retinoic acid receptors: from molecular mechanisms to cancer therapy","volume":"41","author":"di Masi","year":"2015","journal-title":"Mol. Aspects Med."},{"issue":"5","key":"10.1016\/j.bcp.2023.115675_b0020","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ccell.2017.10.002","article-title":"Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure","volume":"32","author":"de Th\u00e9","year":"2017","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bcp.2023.115675_b0025","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.3390\/cancers11101591","article-title":"Acute promyelocytic Leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies","volume":"11","author":"Noguera","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.bcp.2023.115675_b0030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(91)90113-D","article-title":"The PML-RAR\u03b1 fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR","volume":"66","author":"de Th\u00e9","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2023.115675_b0035","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/j.1460-2075.1992.tb05185.x","article-title":"Genomic variability and alternative splicing generate multiple PML\/RAR alpha transcripts that encode aberrant PML proteins and PML\/RAR alpha isoforms in acute promyelocytic leukaemia","volume":"11","author":"Pandolfi","year":"1992","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.bcp.2023.115675_b0040","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/blood.V89.12.4282","article-title":"A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RAR\u03b1 mutation","volume":"89","author":"Shao","year":"1997","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcp.2023.115675_b0045","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/leu.2016.69","article-title":"Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia","volume":"30","author":"Madan","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2023.115675_b0050","doi-asserted-by":"crossref","DOI":"10.1093\/carcin\/bgz014","article-title":"Comparing the epidemiology, clinical characteristics and prognostic factors of acute myeloid leukemia with and without acute promyelocytic leukemia","volume":"40","author":"Kamath","year":"2019","journal-title":"Carcinogenesis"},{"issue":"10","key":"10.1016\/j.bcp.2023.115675_b0055","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood.V90.10.4046","article-title":"Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML)","volume":"90","author":"Falini","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2023.115675_b0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1083\/jcb.201112044","article-title":"Acute promyelocytic leukemia, arsenic, and PML bodies","volume":"198","author":"de Th\u00e9","year":"2012","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115675_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.beha.2014.04.006","article-title":"Understanding the molecular pathogenesis of acute promyelocytic leukemia","volume":"27","author":"Lo-Coco","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115675_b0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1254\/jphs.14R15CP","article-title":"Molecular mechanisms of the antileukemia activities of retinoid and arsenic","volume":"126","author":"Nitto","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.bcp.2023.115675_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.115","article-title":"PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL","volume":"7","author":"Di Masi","year":"2016","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.bcp.2023.115675_b0080","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/s41375-018-0219-5","article-title":"Molecular remission as a therapeutic objective in acute promyelocytic leukemia","volume":"32","author":"Cicconi","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.bcp.2023.115675_b0085","doi-asserted-by":"crossref","first-page":"8505","DOI":"10.3390\/ijms21228505","article-title":"Deciphering the therapeutic resistance in acute myeloid leukemia","volume":"21","author":"Gurnari","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6669","key":"10.1016\/j.bcp.2023.115675_b0090","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/35901","article-title":"Fusion proteins of the retinoic acid receptor-\u03b1 recruit histone deacetylase in promyelocytic leukaemia","volume":"391","author":"Grignani","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bcp.2023.115675_b0095","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccr.2009.12.045","article-title":"PML\/RAR\u03b1 targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia","volume":"17","author":"Wang","year":"2010","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.bcp.2023.115675_b0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ccr.2009.12.042","article-title":"PML-RAR\u03b1\/RXR alters the epigenetic landscape in acute promyelocytic leukemia","volume":"17","author":"Martens","year":"2010","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.bcp.2023.115675_b0105","doi-asserted-by":"crossref","first-page":"12031","DOI":"10.18632\/oncotarget.14509","article-title":"Clonal evolution in therapy-related neoplasms","volume":"8","author":"Fabiani","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115675_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bcp.2023.115675_b0115","article-title":"Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML\/RAR\u03b1 fusion protein","volume":"92","author":"Nervi","year":"1998","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bcp.2023.115675_b0120","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1073\/pnas.96.26.14807","article-title":"Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor \u03b1 (RAR\u03b1) and oncogenic RAR\u03b1 fusion proteins","volume":"96","author":"Zhu","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcp.2023.115675_b0125","article-title":"Arsenic trioxide in the treatment of acute promyelocytic leukemia. A review of current evidence","volume":"90","author":"Sanz","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2023.115675_b0130","first-page":"328","article-title":"Acute myeloid leukemia-genetic alterations and their clinical prognosis","volume":"11","author":"Lagunas-Rangel","year":"2017","journal-title":"Int. J. Hematol. Stem Cell Res."},{"issue":"11","key":"10.1016\/j.bcp.2023.115675_b0135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1200\/JOP.18.00328","article-title":"Treatment of acute promyelocytic leukemia in adults","volume":"14","author":"Osman","year":"2018","journal-title":"J. Oncol. Pract."},{"issue":"13","key":"10.1016\/j.bcp.2023.115675_b0140","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1080\/10428194.2019.1613540","article-title":"Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all","volume":"60","author":"Stahl","year":"2019","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.bcp.2023.115675_b0145","article-title":"Targeting of PI3K\/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance","volume":"4","author":"Estruch","year":"2021","journal-title":"Cancer Drug Resist."},{"issue":"1","key":"10.1016\/j.bcp.2023.115675_b0150","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01228-0","article-title":"Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies","volume":"15","author":"Padella","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2023.115675_b0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13046-022-02360-y","article-title":"Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ER\u03b1 expression and proliferation in luminal primary and metastatic breast cancer cells","volume":"41","author":"Pescatori","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2023.115675_b0160","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.3390\/cancers13071583","article-title":"A tale of ice and fire: the dual role for 17\u03b2-estradiol in balancing DNA damage and genome integrity","volume":"13","author":"Pescatori","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2023.115675_b0165","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-09-0939","article-title":"Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy","volume":"69","author":"Cavelier","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2023.115675_b0170","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aac9704","article-title":"CHK1 as a therapeutic target to bypass chemoresistance in AML","volume":"9","author":"David","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bcp.2023.115675_b0175","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aad8243","article-title":"Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML","volume":"9","author":"Morgado-Palacin","year":"2016","journal-title":"Sci. Signal."},{"issue":"10","key":"10.1016\/j.bcp.2023.115675_b0180","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/bloodadvances.2017015214","article-title":"Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase","volume":"2","author":"Fordham","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcp.2023.115675_b0185","doi-asserted-by":"crossref","first-page":"102026","DOI":"10.1016\/j.ctrv.2020.102026","article-title":"ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias","volume":"88","author":"Boudny","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2023.115675_b0190","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.4161\/cc.8.7.8040","article-title":"Claspin and Chk1 regulate replication fork stability by different mechanisms","volume":"8","author":"Scorah","year":"2009","journal-title":"Cell Cycle"},{"issue":"37","key":"10.1016\/j.bcp.2023.115675_b0195","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1073\/pnas.1005031107","article-title":"Chk1 promotes replication fork progression by controlling replication initiation","volume":"107","author":"Petermann","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bcp.2023.115675_b0200","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ncb1212","article-title":"The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair","volume":"7","author":"S\u00f8rensen","year":"2005","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.bcp.2023.115675_b0205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cell.2007.12.013","article-title":"Chk1 Is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression","volume":"132","author":"Shimada","year":"2008","journal-title":"Cell."},{"issue":"5","key":"10.1016\/j.bcp.2023.115675_b0210","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.cell.2008.03.037","article-title":"Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and Caspase-3","volume":"133","author":"Sidi","year":"2008","journal-title":"Cell."},{"issue":"1","key":"10.1016\/j.bcp.2023.115675_b0215","doi-asserted-by":"crossref","first-page":"e1000324","DOI":"10.1371\/journal.pgen.1000324","article-title":"ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress","volume":"5","author":"Myers","year":"2009","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.bcp.2023.115675_b0220","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1747-1028-5-21","article-title":"Chk1 suppressed cell death","volume":"5","author":"Meuth","year":"2010","journal-title":"Cell Div."},{"key":"10.1016\/j.bcp.2023.115675_b0225","doi-asserted-by":"crossref","DOI":"10.1093\/emboj\/cdg151","article-title":"Human Tousled like kinases are targeted by an ATM- and Chk1-dependent DNA damage checkpoint","volume":"22","author":"Groth","year":"2003","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.bcp.2023.115675_b0230","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.V77.5.1080.1080","article-title":"NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3)","volume":"77","author":"Lanotte","year":"1991","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2023.115675_b0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.leu.2401683","article-title":"A mutated PML\/RARA found in the retinoid maturation resistant NB4 subclone, NB4-R2, blocks RARA and wild-type PML\/RARA transcriptional activities","volume":"14","author":"Duprez","year":"2000","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bcp.2023.115675_b0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.intimp.2014.08.002","article-title":"THP-1 cell line: an in vitro cell model for immune modulation approach","volume":"23","author":"Chanput","year":"2014","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2023.115675_b0245","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.3390\/cells9112423","article-title":"Transcriptional and metabolic dissection of atra-induced granulocytic differentiation in NB4 acute promyelocytic leukemia cells","volume":"9","author":"Albanesi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2023.115675_b0250","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/sj.leu.2401133","article-title":"RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL","volume":"12","author":"Tobal","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2023.115675_b0255","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-2185-x","article-title":"NBS1 interacts with HP1 to ensure genome integrity","volume":"10","author":"Bosso","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2023.115675_b0260","doi-asserted-by":"crossref","unstructured":"Corrigendum to: Hsp90\u03b1 regulates ATM and NBN functions in sensing and repair of DNA double-strand breaks (, FEBS J. 284 (2017) 3968. doi: 10.1111\/febs.14298.","DOI":"10.1111\/febs.14145"},{"key":"10.1016\/j.bcp.2023.115675_b0265","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi, (n.d.)."},{"issue":"7225","key":"10.1016\/j.bcp.2023.115675_b0270","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nature07618","article-title":"Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells","volume":"457","author":"Viale","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2023.115675_b0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.leukres.2017.11.007","article-title":"Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells","volume":"64","author":"Lei","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcp.2023.115675_b0280","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.V97.1.264","article-title":"Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo","volume":"97","author":"Jing","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2023.115675_b0285","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1083\/jcb.201902085","article-title":"Basal CHK1 activity safeguards its stability to maintain intrinsic S-phase checkpoint functions","volume":"218","author":"Michelena","year":"2019","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2023.115675_b0290","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-10-0928","article-title":"Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening","volume":"10","author":"Guzi","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2023.115675_b0295","article-title":"Yang Li-Xi, \u0263 H2AX - A Novel Biomarker for DNA Double-strand Breaks","volume":"22","author":"Kuo","year":"2008","journal-title":"In Vivo (Brooklyn)"},{"issue":"4","key":"10.1016\/j.bcp.2023.115675_b0300","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2011-10-383943","article-title":"CMV-specific cellular therapy for acute myeloid leukemia?","volume":"119","author":"Thomson","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bcp.2023.115675_b0305","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.18632\/oncotarget.6364","article-title":"A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase","volume":"7","author":"Sakurikar","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.bcp.2023.115675_b0310","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1083\/jcb.201406099","article-title":"Rad51-mediated replication fork reversal is a global response to genotoxic treatments in human cells","volume":"208","author":"Zellweger","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bcp.2023.115675_b0315","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-18-2728","article-title":"Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models","volume":"25","author":"Lowery","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2023.115675_b0320","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00280-019-03950-y","article-title":"Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development","volume":"85","author":"Angius","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2023.115675_b0325","doi-asserted-by":"crossref","first-page":"111026","DOI":"10.18632\/oncotarget.22195","article-title":"Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer","volume":"8","author":"Brill","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2023.115675_b0330","first-page":"1","article-title":"Mechanism of action of hydroxyurea","volume":"19","author":"Yarbro","year":"1992","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bcp.2023.115675_b0335","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/sj.leu.2401419","article-title":"In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML\/RAR\u03b1 protein and the PML retargeting on PML-nuclear bodies","volume":"13","author":"Giann\u00ec","year":"1999","journal-title":"Leukemia"},{"issue":"33","key":"10.1016\/j.bcp.2023.115675_b0340","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1038\/sj.onc.1208524","article-title":"Vital functions for lethal caspases","volume":"24","author":"Launay","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2023.115675_b0345","unstructured":"https:\/\/data.mendeley.com\/datasets\/gd4yfvryyh\/2, (n.d.)."},{"key":"10.1016\/j.bcp.2023.115675_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.586004","article-title":"Therapeutic approaches for acute promyelocytic leukaemia: moving towards an orally chemotherapy-free era","volume":"10","author":"Xu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2023.115675_b0355","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/0140-6736(93)92755-I","article-title":"Tretinoin toxicity in children with acute promyelocytic leukaemia","volume":"342","author":"Mahmoud","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2023.115675_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/S0925-5710(96)00578-6","article-title":"Rare but important adverse effects of all-trans retinoic acid in acute promyelocytic leukemia and their management","volume":"66","author":"Hatake","year":"1997","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bcp.2023.115675_b0365","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.165.9.1067","article-title":"Successful treatment of relapsed acute promyelocytic leukemia in a patient receiving continuous ambulatory peritoneal dialysis with oral arsenic trioxide","volume":"165","author":"Au","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.bcp.2023.115675_b0370","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2011-01-329433","article-title":"Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment","volume":"118","author":"Goto","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bcp.2023.115675_b0375","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25573","article-title":"Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse","volume":"94","author":"Iaccarino","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.bcp.2023.115675_b0380","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1073\/pnas.79.9.2942","article-title":"Mechanism by which caffeine potentiates lethality of nitrogen mustard","volume":"79","author":"Lau","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.bcp.2023.115675_b0385","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0960-9822(99)80486-2","article-title":"Caffeine inhibits the checkpoint kinase ATM","volume":"9","author":"Blasina","year":"1999","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2023.115675_b0390","article-title":"Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bcp.2023.115675_b0395","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2014.60.0767","article-title":"Will targeting Chk1 have a role in the future of cancer therapy?","volume":"33","author":"Sakurikar","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2023.115675_b0400","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-12-3748","article-title":"Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776","volume":"19","author":"Engelke","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2023.115675_b0405","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0811-9","article-title":"LSD1\/KDM1A inhibitors in clinical trials: Advances and prospects","volume":"12","author":"Fang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2023.115675_b0410","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.breast.2014.02.004","article-title":"Chk1 as a new therapeutic target in triple-negative breast cancer","volume":"23","author":"Albiges","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.bcp.2023.115675_b0415","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-13-147","article-title":"Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells","volume":"13","author":"Bryant","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2023.115675_b0420","doi-asserted-by":"crossref","DOI":"10.1101\/gad.12.15.2403","article-title":"PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors","volume":"12","author":"Nerlov","year":"1998","journal-title":"Genes Dev."},{"issue":"7","key":"10.1016\/j.bcp.2023.115675_b0425","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.cdd.4400534","article-title":"The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis","volume":"6","author":"Oikawa","year":"1999","journal-title":"Cell Death Differ."},{"issue":"6146","key":"10.1016\/j.bcp.2023.115675_b0430","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1126\/science.1240831","article-title":"Positive feedback between PU.1 and the cell cycle controls myeloid differentiation","volume":"341","author":"Kueh","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bcp.2023.115675_b0435","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2005-07-3068","article-title":"ATRA resolves the differentiation block in t(15;17) acute myeloid leukemia by restoring PU.1 expression","volume":"107","author":"Mueller","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2023.115675_b0440","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-11-0087","article-title":"The drug-induced degradation of oncoproteins: an unexpected achilles\u2019 heel of cancer cells?","volume":"1","author":"Ablain","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2023.115675_b0445","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and Function of the 26S Proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"issue":"8","key":"10.1016\/j.bcp.2023.115675_b0450","doi-asserted-by":"crossref","first-page":"e42721","DOI":"10.1371\/journal.pone.0042721","article-title":"Stress-inducible caspase substrate TRB3 promotes nuclear translocation of procaspase-3","volume":"7","author":"Shimizu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2023.115675_b0455","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-021-02640-y","article-title":"Caspase-3\/NLRP3 signaling in the mesenchymal stromal niche regulates myeloid-biased hematopoiesis","volume":"12","author":"Zhang","year":"2021","journal-title":"Stem Cell Res. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2023.115675_b0460","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1474-9728.2004.00134.x","article-title":"Cellular lifespan and senescence signaling in embryonic stem cells","volume":"3","author":"Miura","year":"2004","journal-title":"Aging Cell"},{"issue":"6","key":"10.1016\/j.bcp.2023.115675_b0465","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.stem.2008.03.012","article-title":"Hematopoietic stem cell responsiveness to exogenous signals is limited by caspase-3","volume":"2","author":"Janzen","year":"2008","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.bcp.2023.115675_b0470","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni.1703","article-title":"The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis","volume":"10","author":"Franchi","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bcp.2023.115675_b0475","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-016-0351-5","article-title":"Novel extracellular and nuclear caspase-1 and inflammasomes propagate inflammation and regulate gene expression: a comprehensive database mining study","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115675_b0480","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.immuni.2019.05.005","article-title":"Inflammasome regulates hematopoiesis through cleavage of the master erythroid transcription factor GATA1","volume":"51","author":"Tyrkalska","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2023.115675_b0485","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207504","article-title":"DNA damage response and immune defense","volume":"21","author":"Nastasi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bcp.2023.115675_b0490","doi-asserted-by":"crossref","first-page":"e4393","DOI":"10.1371\/journal.pone.0004393","article-title":"Ser276 phosphorylation of NF-kB p65 by MSK1 controls SCF expression in inflammation","volume":"4","author":"Reber","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bcp.2023.115675_b0495","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/sj.cdd.4401888","article-title":"NF-\u03baB and the regulation of hematopoiesis","volume":"13","author":"Bottero","year":"2006","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.bcp.2023.115675_b0500","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.immuni.2013.11.022","article-title":"The transcription factor IRF8 activates integrin-mediated TGF-\u03b2 signaling and promotes neuroinflammation","volume":"40","author":"Yoshida","year":"2014","journal-title":"Immunity"},{"issue":"6-7","key":"10.1016\/j.bcp.2023.115675_b0505","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00439-020-02154-2","article-title":"Role of IRF8 in immune cells functions, protection against infections, and susceptibility to inflammatory diseases","volume":"139","author":"Salem","year":"2020","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bcp.2023.115675_b0510","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.603837","article-title":"Metabolism of amino acids in cancer","volume":"8","author":"Wei","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2023.115675_b0515","article-title":"Unraveling the effects of carotenoids accumulation in human papillary thyroid carcinoma","volume":"11","author":"di Masi","year":"2022","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"4","key":"10.1016\/j.bcp.2023.115675_b0520","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1525-1578(10)60476-X","article-title":"Gene expression profiling during all-trans retinoic acid-induced cell differentiation of acute promyelocytic leukemia cells","volume":"5","author":"Yang","year":"2003","journal-title":"J. Mol. Diagnos."},{"issue":"1","key":"10.1016\/j.bcp.2023.115675_b0525","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/sj.leu.2404000","article-title":"Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with Flt3 mutational status","volume":"20","author":"Marasca","year":"2006","journal-title":"Leukemia."},{"key":"10.1016\/j.bcp.2023.115675_b0530","doi-asserted-by":"crossref","first-page":"8129","DOI":"10.3390\/ijms23158129","article-title":"Inflammasomes\u2014new contributors to blood diseases","volume":"23","author":"Tomasik","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2023.115675_b0535","article-title":"The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma","volume":"2","author":"Pajtler","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"issue":"3","key":"10.1016\/j.bcp.2023.115675_b0540","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1006\/geno.1997.5065","article-title":"The human TRIDENT\/HFH- 11\/FKHL16 gene: structure, localization, and promoter characterization","volume":"46","author":"Korver","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.bcp.2023.115675_b0545","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.626836","article-title":"FOXM1 and cancer: faulty cellular signaling derails homeostasis","volume":"10","author":"Kalathil","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2023.115675_b0550","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14590-9","article-title":"FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML","volume":"11","author":"Sheng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2023.115675_b0555","article-title":"Targeting oncogenic Myc as a strategy for cancer treatment","volume":"3","author":"Chen","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2023.115675_b0560","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.canlet.2018.05.011","article-title":"Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR\/Chk1 targeting in medulloblastoma cells","volume":"430","author":"Kr\u00fcger","year":"2018","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bcp.2023.115675_b0565","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/genes10030244","article-title":"Myc oncogene contributions to release of cell cycle brakes","volume":"10","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Genes (Basel)"},{"issue":"20","key":"10.1016\/j.bcp.2023.115675_b0570","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1038\/sj.onc.1205429","article-title":"Human p14arf-mediated cell cycle arrest strictly depends on intact p53 signaling pathways","volume":"21","author":"Weber","year":"2002","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.bcp.2023.115675_b0575","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1074\/jbc.M412330200","article-title":"p14ARF induces G2 cell cycle arrest in p53- and p21-deficient cells by down-regulating p34cdc2 kinase activity","volume":"280","author":"Normand","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2023.115675_b0580","doi-asserted-by":"crossref","DOI":"10.1088\/1475-7516\/2011\/01\/009","article-title":"F(T) gravity mimicking dynamical dark energy. Background and perturbation analysis","volume":"2011","author":"Dent","year":"2011","journal-title":"J. Cosmol. Astropart. Phys."},{"key":"10.1016\/j.bcp.2023.115675_b0585","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2023.115675_b0590","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","article-title":"Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias","volume":"18","author":"Karp","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2023.115675_b0595","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.leukres.2017.09.005","article-title":"Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia","volume":"61","author":"Webster","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcp.2023.115675_b0600","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2443.2005.00840.x","article-title":"Human Rad9 is required for the activation of S-phase checkpoint and the maintenance of chromosomal stability","volume":"10","author":"Dang","year":"2005","journal-title":"Genes Cells"},{"issue":"12","key":"10.1016\/j.bcp.2023.115675_b0605","doi-asserted-by":"crossref","first-page":"e0144434","DOI":"10.1371\/journal.pone.0144434","article-title":"Chk1 activation protects Rad9A from degradation as part of a positive feedback loop during checkpoint signalling","volume":"10","author":"Osorio-Zambrano","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2023.115675_b0610","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1158\/0008-5472.CAN-11-3159","article-title":"The SUMO E3-ligase pias1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA","volume":"72","author":"Rabellino","year":"2012","journal-title":"Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223002666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223002666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:17:40Z","timestamp":1762096660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223002666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":122,"alternative-id":["S0006295223002666"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115675","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RAR\u03b1 and overcomes ATRA resistance in acute promyelocytic leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115675"}}